The groundbreaking aspect of using olaparib in human medicine for treating cancers with BRCA1 and BRCA2 mutations was demonstrated in patients with metastatic breast tumors that harbor BRCA1/2 mutations, achieving an overall response rate (OR) of 50%. This evidence concerns the gene BRCA1 and cancer.